Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CLDN3 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CLDN3 Extracellular Loop (ECL) Recombinant Protein High purity (>95%), Endotoxin controlled, HEK293 expressed (Native Glycosylation). Sequence Verified. |
View CLDN3 Products |
| Gene Delivery | CLDN3 Lentivirus Premade Particles Full-length ORF for stable cell line generation. Preserves native 4-transmembrane conformation. |
View CLDN3 Products |
| Benchmark Ab | Anti-CLDN3 Recombinant Antibody Recombinant positive control for binding and internalization assays. |
View CLDN3 Products |
| Validator | CLDN3 siRNA Set For target knockdown and specificity verification. |
View CLDN3 Products |
| Related Target A | CLDN4 High-homology tight junction protein; essential counter-screening target to prevent off-target toxicity. |
View CLDN4 Products |
| Related Target B | CLDN18.2 Validated tight junction clinical target; useful for comparative selectivity profiling. |
View CLDN18.2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Native Conformation Preservation | Lentivirus Premade Particles for stable cell line generation, enabling flow cytometry and cell-based functional assays. |
| Subfamily Selectivity Screening | High-purity CLDN4 and CLDN6 recombinant proteins for rigorous cross-reactivity and counter-screening panels. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies available as reference standards. |
| False Positives | Validated siRNA sets included for target-specific knockdown verification. |
Live CLDN3 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CLDN3 therapeutics is intensifying, with major players shifting focus from traditional mAbs to antibody-drug conjugates (ADCs) and bispecific antibodies. As first-generation therapies reach the clinic, the next wave of R&D is targeting highly selective epitopes to avoid systemic toxicities associated with tight-junction disruption in normal tissues.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC | Heidelberg Pharma, Hansoh Pharma | Ovarian Cancer, Breast Cancer | Internalization Assay (Need high-purity ECL-Fc and stable cell lines) |
| Bispecific / TCER | Boehringer Ingelheim, Amgen | Solid Tumors, Endometrial Cancer | Selectivity Validation (Need CLDN3/CLDN4 cross-reactive panels) |
| CAR-T / Cell Therapy | Academic Institutions, Biotech Startups | Ovarian Cancer, Mesothelioma | Target Density & Specificity (Need stable CLDN3 overexpressing cells) |